Research Brief
Tirzepatide: Mechanism of Action
1. GLP-2 Receptor — Target and Signaling
Teduglutide is a selective agonist of the GLP-2 receptor (GLP-2R), a class B (secretin-family) G-protein-coupled receptor. GLP-2R is expressed primarily on intestinal subepithelial myofibroblasts (ISEMFs), enteric neurons, and enteroendocrine cells — notably, not directly on intestinal epithelial cells in most species studied. [2]
| Phase | Mechanism | Result |
|---|---|---|
| 1. Receptor binding | Teduglutide binds GLP-2R on ISEMFs and enteric neurons | Gs protein activation → adenylyl cyclase → cAMP ↑ |
| 2. Paracrine signaling | ISEMFs release growth factors (KGF, IGF-1, EGF) | Crypt cell proliferation ↑; villus height ↑; crypt depth ↑ |
| 3. Anti-apoptosis | PI3K/Akt pathway activation in epithelial cells | Enterocyte apoptosis ↓; mucosal barrier integrity ↑ |
| 4. Blood flow | Mesenteric blood flow ↑ via NO and VIP release | Nutrient absorption capacity ↑ |
| 5. Barrier function | Tight junction protein expression ↑ (claudins, occludin) | Intestinal permeability ↓; bacterial translocation ↓ |
2. DPP-4 Resistance — The Gly2→Ala Substitution
Native GLP-2 is rapidly inactivated by DPP-4, which cleaves the His1-Gly2 dipeptide bond at the N-terminus. Replacing Gly2 with alanine (Ala) creates steric hindrance that blocks DPP-4 access while preserving full agonist activity at the GLP-2R. This single substitution transforms the half-life from ~7 minutes to ~2–3 hours in humans — a ~20-fold extension enabling once-daily dosing. [1]
3. Indirect Trophic Mechanism — Paracrine Growth Factors
Because GLP-2R is expressed on ISEMFs rather than directly on crypt epithelial cells, teduglutide’s intestinotrophic effects are indirect — mediated via paracrine release of growth factors: [6]
- Keratinocyte Growth Factor (KGF/FGF-7): Stimulates crypt cell proliferation and goblet cell differentiation
- Insulin-like Growth Factor-1 (IGF-1): Promotes enterocyte growth and anti-apoptotic signaling via PI3K/Akt
- Epidermal Growth Factor (EGF): Enhances epithelial restitution and wound healing
- Vasoactive Intestinal Peptide (VIP): Mediates vasodilatory effects on mesenteric blood flow
4. Downstream Effects on Intestinal Morphology
In human clinical studies with teduglutide, intestinal biopsies demonstrated significant increases in villus height (up to 50–60% increase), crypt depth, and mitotic index in both jejunum and ileum after 24 weeks of treatment. [7] These morphological changes directly translate to increased absorptive surface area, as each villus is lined with nutrient-transporting enterocytes. The net result is enhanced absorption of macronutrients, electrolytes, and fluids — the functional basis for reducing parenteral support requirements.
5. Pharmacokinetics
After subcutaneous injection of 0.05 mg/kg/day (the approved dose), teduglutide reaches Cmax of ~12–21 ng/mL at Tmax of 3–5 hours, with an elimination half-life of approximately 2 hours. Despite the short half-life, the trophic effects accumulate over weeks of daily dosing because intestinal mucosal growth is a cumulative structural process. [8] Teduglutide is primarily cleared via renal elimination of proteolytic fragments; dose reduction is recommended in moderate-to-severe renal impairment.
6. Teduglutide vs. Native GLP-2 vs. Other GLP-2 Analogs
| Property | Native GLP-2 | Teduglutide (Gly2→Ala) | Apraglutide (Phase III) |
|---|---|---|---|
| Half-life | ~7 min | ~2–3 hours | ~30 hours |
| Dosing frequency | N/A (research) | Once daily SC | Once weekly SC |
| DPP-4 resistance | None | Gly2→Ala | Multiple modifications |
| Regulatory status | Not approved | FDA/EMA approved (2012) | Phase III (VectivBio/Ironwood) |
| GLP-2R activity | Full agonist | Full agonist | Full agonist |
References
- Drucker DJ, et al. (1996). Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol, 15(7):673–677.
- Drucker DJ, Yusta B. (2014). Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol, 76:561–583.
- FDA. (2012). NDA 203441 Approval Letter — Gattex (teduglutide) for injection. U.S. Food and Drug Administration.
- Drucker DJ, et al. (1996). Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA, 93(15):7911–7916.
- Jeppesen PB, et al. (2012). Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology, 143(6):1473–1481.
- Leen JLS, et al. (2011). Mechanism of action of glucagon-like peptide 2 to increase IGF-I mRNA in intestinal subepithelial fibroblasts. Endocrinology, 152(2):436–446.
- Jeppesen PB, et al. (2005). Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut, 54(9):1224–1231.
- Gattex (teduglutide) Prescribing Information. (2019). Takeda Pharmaceuticals USA, Inc.
- Schwartz LK, et al. (2016). Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome. Clin Transl Gastroenterol, 7(2):e142.
- Jeppesen PB, et al. (2018). Factors associated with response to teduglutide in patients with short-bowel syndrome and intestinal failure. Gastroenterology, 154(4):874–885.
- Kocoshis SA, et al. (2020). Safety and efficacy of teduglutide in pediatric patients with short bowel syndrome—intestinal failure. J Pediatr Gastroenterol Nutr, 70(4):521–528.
- Hukkinen M, et al. (2019). Parenteral nutrition-associated cholestasis and its association with teduglutide treatment in neonatal short bowel syndrome. J Pediatr Surg, 54(11):2281–2287.
- Drucker DJ, et al. (1999). Glucagon-like peptide 2 reduces intestinal permeability. Am J Physiol, 276(6):G1420–G1426.
Related Research Questions
FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.